Old Web
English
Sign In
Acemap
>
authorDetail
>
Jung Ryun Ahn
Jung Ryun Ahn
Bristol-Myers Squibb
Medicine
Oncology
Internal medicine
relapsed refractory
Interim analysis
3
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Connect ® Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study
2021
Blood
Christopher R. Flowers
David Andorsky
John M. Burke
James R. Cerhan
David L. Grinblatt
Chris L. Pashos
Kathleen Toomey
Andrew D. Zelenetz
Kristen A. Sullivan
E. Dawn Flick
Pavel Kiselev
Mark Kaplan
Jung Ryun Ahn
Show All
Source
Cite
Save
Citations (0)
Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2 ) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
2021
Blood
Frederick Lansigan
David Andorsky
Morton Coleman
Abdulraheem Yacoub
Jason M. Melear
Suzanne R. Fanning
Kathryn S. Kolibaba
C Reynolds
Grzegorz S. Nowakowski
Mecide Gharibo
Jung Ryun Ahn
J. Li
Mathias J. Rummel
Jeff P. Sharman
Show All
Source
Cite
Save
Citations (0)
MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent NHL.
2020
Journal of Clinical Oncology
David Andorsky
Morton Coleman
Abdulraheem Yacoub
Jason M. Melear
Suzanne R. Fanning
Kathryn S. Kolibaba
Frederick Lansigan
Christopher K. Reynolds
Grzegorz S. Nowakowski
Mecide Gharibo
Jung Ryun Ahn
Ju Li
Mathias J. Rummel
Jeff P. Sharman
Show All
Source
Cite
Save
Citations (3)
1